Aethlon Medical, Inc. (AEMD) stock prices were up by a marginal 0.45% as of the market closing on June 8th, 2021, bringing the price per share up to USD$2.21 at the end of the trading day. After-hours trading saw the stock skyrocket by an astounding 92.31%, bringing it up to USDS$4.25.
EUA for Hemopurifier
The company recently announced the positive results from use of Aethlon Hemopurifier in treating two patients who were critically ill with Covid-19, with neither patient expected to survive. The dire circumstances merited the granting of emergency use authorization (EUA) by the FDA. That is to say, the treatment has not yet been fully approved by the U.S. Food and Drug Administration, but was allowed because of the absence of any other viable options.
The first patient was administered the Hemopurifier treatment daily, with adequate tolerance of the procedure and no signs of allergic reaction, thrombotic complications, or hemolysis. The treatment regimen resulted in the patient being observed without any demonstrable Covid-19 viremia, the active circulation of the virus in the bloodstream. Viremia has been associated with disease severity and the progression to multi-organ failure.
Efficacy of Treatment
The treatment resulted in improvements in Covid-19 associated coagulopathy (CAC), lung injury, inflammation, and tissue injury. Consequently, the company is confident that the improvements are a reflection of the treatment’s ability to remove exosome with noxious microRNA cargo. This removal of exosomes is what AEMD’s posits contributed the patient’s recover.
Results of Hemopurifier
The patient exhibited decreases in total exosomal concentration in the patient as compared to reports from before the administering of the Hemopurifier treatment. The patient’s lung injury also showed signs of having improved as a result of the treatment. The regimen included eight Hemopurifier treatments, none of which had any complication. The patient was ultimately weaned from a ventilator and eventually discharged from the hospital.
Scope of Treatment
These findings support the claim that the benefits of the Hemopurifier treatment in Covid-19 has the potential to be useful beyond virus removal in its capacity to eliminate exosomes. As the treatment is being evaluated for its efficacy in removing exosomes to treat patients with cancer, the treatment of the Covid-19 patient shows that exosomes are also involved in the cell-to-cell spread of Covid-19 infection and its associated inflammation coagulopathy, and complement activation.
Future Outlook for AEMD
With the world hurtling towards global immunizations, AEMD is poised to capitalize on these efforts with the commercialization and proliferation of its Hemopurifier treatment. Current and potential investors are hopeful that management will leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value.